{
  "retracted": false,
  "timestamp": 1454457600000,
  "updates": [
    {
      "timestamp": 1495642041751,
      "identifier": {
        "doi": "10.1186/s13063-016-1195-6"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1186/s13063-015-1101-7"
  },
  "publisher": "Springer Nature",
  "title": "Erratum to: â€˜Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial"
}
